Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial

BACKGROUND: Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy (hazard ratio 0.76; 95% confidence interval, 0.59–0.98; two-sided P = 0.03). We report safety, therapy management, and pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Staehler, M, Motzer, R J, George, D J, Pandha, H S, Donskov, F, Escudier, B, Pantuck, A J, Patel, A, DeAnnuntis, L, Bhattacharyya, H, Ramaswamy, K, Zanotti, G, Lin, X, Lechuga, M, Serfass, L, Paty, J, Ravaud, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247664/
https://www.ncbi.nlm.nih.gov/pubmed/30412222
http://dx.doi.org/10.1093/annonc/mdy329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247664/
https://www.ncbi.nlm.nih.gov/pubmed/30412222
http://dx.doi.org/10.1093/annonc/mdy329

Ejemplares similares